Bosh sahifa038290 • KOSDAQ
add
Macrogen Inc
Yopilish kursi
16 140,00 ₩
Kunlik diapazon
15 980,00 ₩ - 16 170,00 ₩
Yillik diapazon
14 700,00 ₩ - 24 600,00 ₩
Bozor kapitalizatsiyasi
174,11 mlrd KRW
Oʻrtacha hajm
27,60 ming
Narx/foyda
-
Dividend daromadliligi
1,87%
Asosiy maydon
KOSDAQ
Bozor yangiliklari
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (KRW) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Daromad | 40,97 mlrd | 10,96% |
Joriy xarajat | 13,50 mlrd | -0,90% |
Sof foyda | 647,85 mln | 104,81% |
Sof foyda marjasi | 1,58 | 104,33% |
Har bir ulushga tushum | — | — |
EBITDA | -359,97 mln | -108,84% |
Amaldagi soliq stavkasi | 180,66% | — |
Balans
Jami aktivlari
Jami passivlari
| (KRW) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 42,62 mlrd | 68,38% |
Jami aktivlari | 329,66 mlrd | 27,87% |
Jami passivlari | 152,23 mlrd | 57,17% |
Umumiy kapital | 177,43 mlrd | — |
Tarqatilgan aksiyalar | 10,84 mln | — |
Narxi/balansdagi bahosi | 1,09 | — |
Aktivlardan daromad | -2,53% | — |
Kapitaldan daromad | -3,24% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (KRW) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Sof foyda | 647,85 mln | 104,81% |
Operatsiyalardan naqd pul | 9,39 mlrd | -19,72% |
Sarmoyadan naqd pul | -3,41 mlrd | 55,76% |
Moliyadan naqd pul | 6,95 mlrd | 338,08% |
Naqd pulning sof oʻzgarishi | 12,72 mlrd | 164,49% |
Boʻsh pul | -5,18 mlrd | -163,87% |
Haqida
Macrogen, Inc. is a South Korean public biotechnology company. The company's headquarters are located in Seoul. The company was founded in 1997 by Jeong-sun Seo, a professor at Seoul National University. It was venture capital-backed until its initial public offering and subsequent listing on the KOSDAQ market in 2000, making it the first Korean biotechnology firm to raise funds through an IPO. The company announced plans in 2010 to map the "Korean genome" based on the notion that United States-backed genome mapping efforts up to that time were representative of the "Caucasian genome" rather than the "Human genome" as claimed. By 2015, the company was described by one news outlet as "a global leader in personalized genomic medicine". Wikipedia
Tashkil etilgan
5-iyn, 1997
Sayt
Xodimlar soni
519
